Showing 1–14 of 14 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Amyn A. Malik, Mercedes C. Becerra, Hamidah Hussain
…rnational guidance underscore the benefits of TB preventive treatment for household contacts of all ages [[1]World Health OrganizationWHO operational handbook on tuberculosis: module 1: prevention: tuberculosis preventive treatment. World Health Organization, Geneva, Switzerland2…
Kendra Brett, Camille Dulong, Melissa Severn
…eing pulmonary TB.,Individuals with TB are categorized into latent TB infection (LTBI) and active TB disease., LTBI refers to an individual who has the M. tuberculosis infection in which the bacteria are alive but are not currently causing active TB disease. Persons with LTBI do …
Alissar Al Khatib, Salwa Hassanein, Mohammad Almari, Mohamad Koubar, Suha Fakhreddine
…s was highly recommended by World Health Organization (WHO) guidelines (WHO, 2023). Although death is preventable by successful treatment, a great number of TB survivors experience post-tuberculosis conditions, with an increase of long-term disability evidence in this population …
Kendra Brett, Camille Dulong, Melissa Severn
…ion of TB bacteria.Individuals with TB are categorized into latent TB infection (LTBI) and active TB disease., LTBI refers to an individual who has the M. tuberculosis infection in which the bacteria are alive but are not currently causing active TB disease. Persons with LTBI do …
Valentina Aksenova, Nadezda Klevno, Alexey Kazakov, А. Д. Пахлавонова
…to WHO, the effectiveness of currently available preventive treatment schemes for people of the risk groups is from 60 to 90%. However, up to date, preventive treatment guidelines have not been developed for people who have been in contact with patients with MDR-TB. Objective of …
Vladimir Milanov, Nikolay Yanev, Natalia Gabrovska, Denitsa Dimitrova, Elizabeta Bachiyska, et al.
Isoniazid (H; INH) is an important first-line drug for the treatment of active tuberculosis (TB) and latent TB infection because of its potent early bactericidal activity against Мycobacterium tuberculosis. Currently, TB resistant to INH, alone or in combination with other drugs,…
Jyoti S. Mathad, Sylvia M. LaCourse, Amita Gupta
…ganization (WHO) recommends improving access to testing and treatment of latent TB infection (LTBI) [1]. Despite recent epidemiologic studies demonstrating an approximately twofold increased risk of active TB in peripartum women [2], and poor outcomes associated with TB during pr…
R. De Luca E Tuma, Amina Jama, Susan Dart, Verónica White, Christabelle Chen, et al.
…of MDR-TB in East London remain high. There are no existing guidelines for treating close contacts of newly diagnosed MDR-TB cases in low TB incidence countries. This study aims to analyze the rates of MDR-TB among close contacts of TB index cases with pulmonary MDR-TB in East Lo…
Suman Majumdar, Rina Triasih, Stephen M. Graham
…is by 2030 cannot be achieved without a strategy to address latent infection that is subclinical or quiescent.2Rangaka MX Cavalcante SC Marais BJ et al.Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection.Lancet. 2015; 386: 2344-2353Summary …
Alberto L. García‐Basteiro, Helen E. Jenkins, Molebogeng X. Rangaka
…uggest that around 25% of the world's population could have latent tuberculosis infection,2Houben RMGJ Dodd PJ The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling.PLoS Med. 2016; 13e1002152Crossref PubMed Scopus (933) Google Scholar 5–…
Nathan Kapata, Alimuddin Zumla
An estimated 1·7 billion people globally are latently infected with Mycobacterium tuberculosis.1WHOGlobal tuberculosis report 2021.https://www.who.int/publications/i/item/9789240037021Date: October 14, 2021Date accessed: March 19, 2022Google Scholar Latent M tuberculosis infectio…
Neil W. Schluger
…treated with isoniazid (INH) according to Peruvian national guidelines in Peru Topics discussed include vaccine candidates in phase trials after cases of coronavirus disease (COVID-19), clinical trials examining treatment for latent TB and infectious disease challenge in hospital…
Gavin Churchyard, MBBCh MMed FRCP FCP(SA) PhD, Amita Gupta, MD, MHS, Anneke Hesseling, MD, PhD, Susan Swindells, MBBS
…-risk HHCs are those with HIV or non-HIV immunosuppression, latent TB infection, and young children below the age of 5 years. This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing confirmed or probable ac…
Robert I. Anderson, Eleanor Sheppard, Jun Yong, Alastair Yeoh, Thomas Seddon, et al.
…tion and management requires multi-disciplinary approach. • Latent TB screening in haematological malignancy is challenging. • Better evidence-based risk-stratification screening tools are needed. Current data indicate a rising incidence of tuberculosis in the UK, affecting both …